Peter A. McCullough, MD, MPH™
Open in Telegram
Physician, author, news commenator, pandemic response, civil liberties, and path forward, www.petermcculloughmd.com
Show more📈 Analytical overview of Telegram channel Peter A. McCullough, MD, MPH™
Channel Peter A. McCullough, MD, MPH™ (@p_mcculloughmd) in the English language segment is an active participant. Currently, the community unites 15 545 subscribers, ranking 1 572 in the Medicine category and 2 408 in the USA region.
📊 Audience metrics and dynamics
Since its creation on невідомо, the project has demonstrated rapid growth, gathering an audience of 15 545 subscribers.
According to the latest data from 07 September, 2026, the channel demonstrates stable activity. Although there has been a change in the number of participants by -29 over the last 30 days and by -2 over the last 24 hours, overall reach remains high.
- Verification status: Not verified
- Engagement rate (ER): The average audience engagement rate is 13.61%. Within the first 24 hours after publication, content typically collects 7.18% reactions from the total number of subscribers.
- Post reach: On average, each post receives 2 116 views. Within the first day, a publication typically gains 1 116 views.
- Reactions and interaction: The audience actively supports content: the average number of reactions per post is 25.
- Thematic interests: Content is focused on key topics such as vaccine, covid-19, mrna, peter, medicine.
📝 Description and content policy
The author describes the resource as a platform for expressing subjective opinions:
“Physician, author, news commenator, pandemic response, civil liberties, and path forward, www.petermcculloughmd.com”
Thanks to the high frequency of updates (latest data received on 08 September, 2026), the channel maintains relevance and a high level of publication reach. Analytics show that the audience actively interacts with content, making it an important point of influence in the Medicine category.
15 545
Subscribers
-224 hours
-17 days
-2930 days
Data loading in progress...
Similar Channels
Tags Cloud
Incoming and Outgoing Mentions
---
---
---
---
---
---
Attracting Subscribers
September '26
September '26
+32
in 14 channels
August '26
+116
in 64 channels
Get PRO
July '26
+140
in 94 channels
Get PRO
June '26
+154
in 158 channels
Get PRO
May '26
+199
in 101 channels
Get PRO
April '26
+112
in 68 channels
Get PRO
March '26
+125
in 74 channels
Get PRO
February '26
+108
in 41 channels
Get PRO
January '26
+115
in 49 channels
Get PRO
December '25
+112
in 32 channels
Get PRO
November '25
+142
in 59 channels
Get PRO
October '25
+105
in 61 channels
Get PRO
September '25
+146
in 84 channels
Get PRO
August '25
+179
in 77 channels
Get PRO
July '25
+121
in 45 channels
Get PRO
June '25
+191
in 67 channels
Get PRO
May '25
+195
in 97 channels
Get PRO
April '25
+191
in 43 channels
Get PRO
March '25
+192
in 48 channels
Get PRO
February '25
+246
in 91 channels
Get PRO
January '25
+396
in 112 channels
Get PRO
December '24
+254
in 65 channels
Get PRO
November '24
+249
in 133 channels
Get PRO
October '24
+211
in 62 channels
Get PRO
September '24
+219
in 43 channels
Get PRO
August '24
+226
in 68 channels
Get PRO
July '24
+152
in 84 channels
Get PRO
June '24
+255
in 112 channels
Get PRO
May '24
+365
in 110 channels
Get PRO
April '24
+296
in 104 channels
Get PRO
March '24
+257
in 164 channels
Get PRO
February '24
+254
in 93 channels
Get PRO
January '24
+314
in 126 channels
Get PRO
December '23
+303
in 97 channels
Get PRO
November '23
+273
in 99 channels
Get PRO
October '23
+336
in 103 channels
Get PRO
September '23
+418
in 0 channels
Get PRO
August '23
+480
in 0 channels
Get PRO
July '23
+518
in 0 channels
Get PRO
June '23
+374
in 0 channels
Get PRO
May '23
+473
in 0 channels
Get PRO
April '23
+670
in 0 channels
Get PRO
March '23
+697
in 0 channels
Get PRO
February '23
+951
in 0 channels
Get PRO
January '23
+2 562
in 0 channels
Get PRO
December '22
+6 202
in 0 channels
| Date | Subscriber Growth | Mentions | Channels | |
| 08 September | +1 | |||
| 07 September | +2 | |||
| 06 September | +5 | |||
| 05 September | +3 | |||
| 04 September | +3 | |||
| 03 September | +9 | |||
| 02 September | +2 | |||
| 01 September | +7 |
Channel Posts
The NIH government protocol for COVID-19 never met the intensity, complexity, and full range of options in the McCullough Protocol™ for patients with acute, high-risk SARS-CoV-2. Sadly, most patients were inadequately treated at home and in the hospital.
@P_McCulloughMD
| 2 |  Pandemic response was never taught in medical school. When SARS-CoV-2 hit America in 2020, it was a challenge test for the medical orthodoxy. Few passed. I am proud of the doctors and nurses who stepped into the gap preventing hospitalizations and death and the Wellness Company who has carried us forward since 2022. Courtesy Grant Stinchfield.
@P_McCulloughMD | 655 |
| 3 |  A Protocol Is a FLOOR, Not a Ceiling
Guidelines exist to set a minimum standard when a clinician has nothing better to go on. They were never meant to outrank the physician looking at an actual patient. During the pandemic that inverted — deviating became a liability exposure and a licensure risk instead of the exercise of judgment it's supposed to be. It's easy to blame individual doctors. It's harder to admit the system made independent thinking personally expensive, then acted surprised when almost nobody did it.
@P_McCulloughMD | 1 161 |
| 4 |  "I Don't See It the Way You See It" Is Not a Diagnosis
A patient who reports a new symptom after an intervention deserves the same workup they'd get if it had appeared out of nowhere. Rule out what's rule-out-able, document what's left, and say plainly when you don't know. People aren't walking away from medicine because a doctor disagreed with them.
They're walking away because they were told their experience DIDN'T HAPPEN. "I don't know, but let's find out" keeps a patient who'd otherwise be building a treatment plan alone at 2am.
@P_McCulloughMD | 1 050 |
| 5 |  RECOVER-VITAL: Why Paxlovid Was Destined to Fail Against Long COVID
The NIH Trial That Treated the Wrong Disease in the Wrong Patients While Ignoring the One Variable That Actually Matters--Spike Protein.
@P_McCulloughMD | 1 021 |
| 6 |  Proving a Drug Works and Proving It's Safe Don't Require the Same Evidence
Efficacy needs a large randomized trial — you're pulling a real signal out of statistical noise, and that takes power. Harm works differently. A small number of stark events is ENOUGH to warrant investigation. That isn't a lowered standard, it's how pharmacovigilance has always worked, and it's the entire reason post-market surveillance exists. The failure mode is demanding trial-grade certainty before anyone will take a safety signal seriously.
@P_McCulloughMD | 1 135 |
| 7 |  +1Coalition for Epidemic Preparedness and Innovation (CEPI) is banking on another laboratory-generated pandemic. Here is what they are doing about it: >75 vaccine candidates being developed for Disease X with > 470 R&D partners. CEPI's business model is heading your way. Courtesy AMI365.
@P_McCulloughMD | 1 362 |
| 8 |  Trump’s Three Bold Steps to Secure America’s Drug Supply Chain
Drug shortages can be a national security risk. This is what the administration has done to ensure you have access to the medications you depend on.
@P_McCulloughMD | 1 343 |
| 9 |  A platform doesn't get approved. Products do.
RSV, flu, cancer — all coming on the same mRNA backbone.
Here's what that backbone can't do: carry a safety record from one product to the next.
Different antigen. Different dose. Different population. Different risk.
Each needs its own trial. Each needs its own scrutiny.
Fast to manufacture is not the same as proven.
@P_McCulloughMD | 1 675 |
| 10 |  Shingles has a 72-hour window. Most people miss it.
Antivirals work best within 3 days of the rash. Start late and your odds of postherpetic neuralgia — nerve pain lasting months or years — go up sharply.
The warning comes before the blisters: burning, itching, or strange sensitivity in a band on one side.
Near your eye? ER. Not tomorrow.
Few conditions where days matter this much.
@P_McCulloughMD | 1 531 |
| 11 |  Watch what a vaccine ad stops talking about.
When the pitch shifts from "prevents shingles" to heart benefits, brain benefits, general wellness — read that.
Those findings come from observational data. Healthier people get vaccinated more. That's the confounder, and it's brutal to eliminate.
One question matters: does it prevent shingles, in a patient like you, at a risk you accept.
The rest is marketing.
@P_McCulloughMD | 1 392 |
| 12 |  The Shingles Shot Scam: What Your Doctor Won't Tell You About the Vaccine Cartel's Latest Push
Shingles vaccine is more potent than chickenpox shot, lasts only 3–5 years, causes serious inflammation, and has zero proven ancillary benefits — despite what the marketing campaign claims.
@P_McCulloughMD | 1 449 |
| 13 |  A Man Without a Spleen Needs Those Vaccines. That's Not the Same Patient as Everyone Else.
Asplenia leaves someone genuinely defenseless against encapsulated bacteria — pneumococcus, meningococcus, Hib — and for that patient the case is overwhelming. Individual risk assessment is what medicine is supposed to be. What it has drifted toward is a single recommendation applied to every body regardless of age, history, or exposure, in a system where uptake is the metric everyone is graded on. Risk stratification isn't a rejection of vaccines. It's the difference between a physician and a protocol.
@P_McCulloughMD | 1 603 |
| 14 |  Most of America's Antibiotics Start as Ingredients Made in India or China
The active pharmaceutical ingredients behind common generics are largely produced overseas, and the last remaining U.S. penicillin fermentation plant closed decades ago. That's a supply chain a trade dispute or a shipping disruption can sever — and antibiotics aren't optional. New domestic production commitments are a real step toward fixing it. Drug shortages hit the poorest and sickest patients first, every time. Making the basics at home isn't protectionism; it's the same logic as any other strategic reserve.
@P_McCulloughMD | 1 527 |
| 15 |  Stay Home When You're Actually Sick. That's the Part We Got Backwards.
Healthy people isolating for months accomplished little. Sick people going in anyway is how transmission actually happens — and it's still normal, still expected, still rewarded in most workplaces. The unglamorous measures do the work: stay home when symptomatic, sleep separately during an acute illness, wash your hands, get real sleep. Nasal rinses and gargles are cheap and low-risk. None of it requires anyone's permission, and it's more within your control than anything an agency recommends.
@P_McCulloughMD | 1 483 |
| 16 |  Apply the Same Standard to Every Death Count, Every Time.
Millions of Americans spent four years arguing that "died with" and "died of" are different things, and they were right to. That standard doesn't get suspended when a different disease is in the headlines. Cause of death should be adjudicated by the coroner, documented, and published — before it becomes a number in a press release. Careful attribution is what separates public health from public relations, and it's the only way any death count earns the trust it's asking for.
@P_McCulloughMD | 1 342 |
| 17 |  Federal Records Law Isn't a Formality. It's the Only Reason Any of This Ever Surfaced.
Emails sent by federal officials on government business belong to the public, subject to FOIA. That statutory obligation is why subpoenaed correspondence exists to be read at all — and it's why a senior NIAID adviser has now pled guilty to conspiring to evade it. Any instruction to delete after reading defeats the entire architecture of oversight. Informed consent begins upstream of the exam room: it begins with a record that can be examined.
@P_McCulloughMD | 1 312 |
| 18 |  BREAKING: STUDY FINDS mRNA “VACCINES” COULD INDUCE OR ACCELERATE CANCER VIA 35 DISTINCT MECHANISMS
The most comprehensive analysis to date examining the link between mRNA “vaccines” and cancer identifies convergent mechanistic, clinical, and population-level evidence of turbo cancer.
@P_McCulloughMD | 1 704 |
| 19 |  You Came In for an Ear Infection. Why Are They Swabbing You for COVID?
A test is worth running when the result changes what happens next. For a healthy adult with cold symptoms in 2026, it usually doesn't — the treatment is the same either way. Where it still matters is a patient with real comorbidities, where an antiviral decision hinges on the answer. Reflexive testing on every visit isn't caution; it's a billing line that outlived its clinical purpose. Ask what will change based on the result. If the answer is nothing, ask why it's being ordered.
@P_McCulloughMD | 1 447 |
| 20 |  Lockdowns: Point Was to Delay Natural Immunity, NOT to Protect the Vulnerable
Widespread natural immunity would diminish the ecstatic embrace of the heralded vaccine “Savior.” by John Leake
@P_McCulloughMD | 1 494 |
